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To our knowledge, no study has evaluated N-terminal pro-brain natriuretic peptide (NTproBNP)
together with interleukin-6 (IL-6) and interferon (IFN)-gamma serum levels in a large series of patients
with hepatitis C virus (HCV) as possible markers of cardiac dysfunction. NTproBNP and IL-6 serum
levels were valued in 55 HCV-patients, and in 55 sex- and age-matched controls. HCV-patients showed
significantly higher mean NTproBNP and IL-6levels than controls (P= 0.001); no significant difference
was observed for IFN-gamma. By defining high NTproBNP level as a value higher than 300 pg/mL
(that is used to rule out heart failure in patients under 75 years of age), 12% (6/49) of HCV-patients
and 0 of controls had NTproBNP (X2 ; P = 0.012). In conclusion, this study demonstrates high levels of
circulating NTproBNP and IL-6 in HCV-patients. The increase ofNTproBNP may indicate the presence
of a subclinical cardiac dysfunction. Further prospective studies quantifying symptoms and correlating
these with echocardiographic parameters are needed to confirm this association.
Several studies have suggested that hepatitis C
virus (HCY) infection is frequently found in patients
with dilated cardiomyopathy (1, 2), and moreover,
it has been suggested that HCY infection may
contribute to the development of this unusual form
of myocarditis (3-6).
Furthermore, it has been shown that interleukin-6
(lL-6) and NTproBNP are independent predictors of
long-term risk of death or heart failure (HF) (7, 8).
However, to date, to our knowledge, no study has
evaluated NTproBNP together with lL-6 in HCY,
while only few studies have evaluated the importance
oflL-6 in HCY-patients, most ofwhich showed high
IL-6 levels in these patients (9, 10).
The aim of this study is to evaluate serum levels
of NTproBNP and IL-6 in a series of HCY-patients,
and to correlate these parameters with the clinical
features of the disease.
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MATERIALS AND METHODS
Patients
Fifty-five HCY-patients (39 F and 16 M; mean
age 56±1O SD years), consecutively referred to the
Department ofIntemal Medicine, University ofPisa, Italy,
were enrolled in the study between 2001 and 2006. HCY-
patients without cryoglobulinemic syndrome (without
other liver infection) were selected from a larger cohort
of 491 chronic hepatitis referrals, without liver cirrhosis
(by histology, laboratory evidence of liver failure and/or
ultrasound-proven portal hypertension) (II); exclusion
criteria were cancer, clinical and laboratory evidence of
thyroid disorders and/or autoimmune diseases, treatment
with immunomodulators, arterial hypertension, renal
disorders, or diabetes. Forty/55 (73%) HCY-patients
underwent liver biopsy for diagnostic purposes; liver
histology activity index (grade), or stage of liver fibrosis
were evaluated according to Ishak et al. (12). The mean
activity index (grade) in HCY-patients was 5.1±1.2, and
the stage was 2.0±0.2. Routine blood chemistry was
carried out by standard methods.
Controls
Each ofthe 55 HCY-patients eligible for the study was
matched, by sex and age, one-to-one with a control group
of healthy subjects of the general population from the
same geographic area (North-West Tuscany). This control
group was extracted from a larger sample of 1640 HCY-
negative subjects in a population-based survey of thyroid
disorders; exclusion criteria were the same as those of
the HCY patients. When more than one age-match was
available per case, the choice was made at random.
The study protocol was approved by the local Ethics
Committee. All subjects gave their informed consent to
enter the study.
Virological studies
Antibodies against HCY (Anti-HCY) and HCY-
RNA were determined on serum clotted and centrifuged
at 37°C and stored at -80°C. Anti-HCY and HCY-RNA
(polymerase chain reaction -PCR- technique) in the serum
were investigated as previously described (II).
Cytokines, chemokines and analytical assays
Blood samples for analysis ofplasma NTproBNP were
collected and centrifuged, and plasma was stored at -80°C
until analysis. Circulating concentrations of NTproBNP
were measured by a sandwich immunoassay on an Elecsys
2010 (Roche Diagnostics, Mannheim, Germany).
Serum IL-6 and interferon (IFN)-gamma levels were
assayed by a quantitative sandwich immunoassay using
commercially available kits (R&D Systems, Minneapolis,
MN, USA), with a sensitivity of 0.7pg/mL, and 9pg/ml,
respectively.
Serum IFN-gammaconcentrations were measured using
commercially available kits (R&D Systems). The mean
minimum detectable dose was 9pgiml for IFN-gamma; the
intra- and inter-assay coefficients of variation were 2.8%
and 6.1%, respectively. Samples were assayed in duplicate.
Quality controlpools of low, normal, or high concentration
for all parameterswere included in each assay.
Data analysis
Valuesare given as mean ± SD for normally distributed
variables, or as median ± IQR for not normally distributed
variables (NTproBNP, IL-6). Group values were compared
by univariate ANOYA, for normally distributed variables;
or by Kruskal-Wallis (~ 3 groups) or Mann-Whitney
U (2 groups) tests. Proportions were compared by the
X2 test. Post-hoc comparisons on normally distributed
variables were carried out using the Bonferroni-Dunn test.
Univariate analysis was performed by simple regression.
A Spearman rank correlation for NTproBNP and IL-6
was made. A multivariate logistic regression analysis
considering age, gender, ALT,and presence or absence of
high levels of NTproBNP or IL-6 as dependent variables
was carried out on HCY-patients.
RESULTS
Plasma NTproBNP concentrations were
significantly (P < 0.001) higher in HCY-patients
(mean 120±174 ng/L; median 38pg/mL, range
7-1891), than in controls (mean 17±19 ng/L; median
2.7ng/L, range 1.2-121) (Fig. 1).
By defining high NTproBNP level as a value
higher than 125pg/mL [the single cut-off point for
outpatients under 75 years of age (13)] 20/35 HCY-
patients and 5/50 controls had high NTproBNP (X2;
P< 0.001).
With a cut-off point of 300pg/mL [that is used
to rule out HF in patients under 75 years of age
(13)] 6/49 HCY-patients and 0/55 controls had high
NTproBNP (X2; P = 0.012).
With a cut-off point of900pg/mL [that should be
used for ruling in HF in patients aged 50-75; such as
the patients of our study (13)], 4/51 HCY-patients
and 0/55 controls had high NTproBNP (X2; P =
0.042) (Table I).
In order to better define the role of increased
serum NTproBNP in HCY-patients, mean levels of
NTproBNP were separately evaluated (by Mann-
Whitney U test) among HCY-patient subgroups
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Table I. The prevalence ofHCV-patients with high circulating NTproBNP levels was higher than in controls.
NTproBNP HCV+ Controls X2
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Fig. 1. Plasma NTproBNP concentrations in HCV-patients and controls. HCV-patients showed significantly higher mean












Fig. 2.1L-6 serum levels in HCV-patients and controls. HCV-patients showedsignificantly higher mean (± SE) 1L-6 serum
levels than controls (P = 0.005; Mann-Whitney U test).
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defined according to main demographic and clinical
features (age> 55 years; gender; disease duration>10
years; aminostransferase elevation and/or histologic
activity in the liver), but no significance was found.
No significant correlations were observed between
NTproBNP and serological findings ofHCY-patients
or previous/ongoing treatments.
Patients with HCY showed significantly (P =
0.005; Mann-Whitney U test) higher mean IL-6
serum levels (mean 54±16 ng/L; median lOng/L,
range 0.6-452), than controls (mean 11±6 ng/L;
median 0.9ng/L, range 0.6-43) (Fig. 2). By defining
high IL-6 level as a value higher than the 95th
percentile ofthe control group (> 23pg/mL), 79% of
HCY-patients and 6% of the control subjects had a
high IL-6 level (P < 0.001; X2) .
In order to better define the role ofincreased serum
IL-6 in HCY-patients, mean levels ofthis chemokine
were separately evaluated (by Mann-Whitney U test)
among HCY-patient subgroups defined according
to the main demographic and clinical features (age
> 55 years; gender; disease duration >10 years;
aminostransferase elevation and/or histologic
activity in the liver), but no significance was found.
No significant correlations were observed between
IL-6 and serological findings of HCY-patients or
previous/ongoing treatments.
HCY-patients had, obviously, raisedALT enzymes
(P < 0.0001), in comparison with controls. Elevated
levels of NTproBNP or IL-6 were not associated
with serum HCY-RNA level or HCY genotype. No
association was observed between NTproBNP or
IL-6 and ALT levels in HCY-patients.
Spearman rank correlation for NTproBNP and
IL-6 was made showing not significant results (Rho
0.133;Z-value 1.01;P=0.31).
IFN-gamma was detectable in the serum of9% of
controls, 16% of HCY+ patients; IFN-gamma levels
were not significantly different in the two groups.
No relation was found between IFN-gamma and
NTproBNP or IL-6.
DISCUSSION
Our study demonstrates significantly high serum
levels of NTproBNP together with IL-6 in patients
with HCY-patients compared to healthy controls.
Some authors have recently stated that NTproBNP
appears superior to BNP for the evaluation of
suspected acute HF in patients with preserved left
ventricular ejection fraction (13). The International
Collaborative for NTproBNP Study (ICON) helped
to define appropriate cut-off points for NTproBNP
in the emergency department (13): 300pg/mL should
be used to rule out HF, while 450pg/mL, 900pg/mL,
or 1800pg/mL - depending on age « 50, 50-75, or>
75 years; respectively) - should be applied for ruling
in HE For outpatient evaluation, the manufacturer
suggested a single cut-off point of 125pg/mL for
patients under 75 years of age and 450pg/mL for
patients over 75 years of age (13).
The levels of NTproBNP found in HCY-patients
are comprised in a gray zone (125-900 pg/mL), that is
not necessarily associated with HF, however in 4/55
(7%) of HCY-patients the NTproBNP levels were
higher than 900pg/mL, which is the cut-off value for
ruling HF in patients aged 50-75, such as the patients
in our study. Since, NTproBNP seems to correlate
with HF severity, the values in the gray zone may be
suggestive of a subclinical cardiac impairment.
Our data agree with other studies in that HCY
infection may contribute to the development of this
unusual form of myocarditis, frequently associated
with myocardial antibodies and responsive to
immunosuppressive therapy (3-6). In fact, the
present study suggests that HCY may be an
important agent in causing dilated cardiomyopathy
and chronic HF and that elevated plasma NTproBNP
levels may correlate with the clinical features of the
disease. Other studies have suggested that HCY
infection is frequently found in patients with dilated
cardiomyopathy (1, 2). However, other studies
were not able to find an association between HCY
infection and dilated cardiomyopathy (14, 15). In a
retrospective study, it was shown that NTproBNP is
a sensitive marker of myocardial injury in patients
with HF from HCY myocarditis (4).
Furthermore, elevated levels ofNTproBNP during
and after interferon-based antiviral therapy of HCY
have been found, suggesting the presence of cardiac
dysfunction (16). However, no conclusion could be
drawn in this study regarding baseline NTproBNP
levels in HCY-patients lacking an internal control
(16). Interestingly, the median NTproBNP levels in
our HCY-patients are quite similar to those of the
baseline value of the patients of that study (36 vs
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37 pg/mL; respectively), and another study of our
group (17). Furthermore, NTproBNP levels in HCV
patients were similar to those observed in HCV-
associated cryoglobulinemia (18).
The findings of the present study may have
important implications for patients with HCV.
Most patients complain about fatigue, dyspnea
and reduced physical capacity. The pathogenesis
of these symptoms is not well understood and is
sometimes attributed to the liver injury. However, it
seems possible that these patients experience cardiac
impairment at least contributing to these symptoms.
Testing of NTproBNP may serve as a screening
marker for cardiac insufficiency in the differential
diagnosis of fatigue and dyspnea and may alleviate
the decision for further diagnostic testing of cardiac
function as it has been described for other groups of
patients (19, 20). Besides diagnostic consequences,
evaluation of NTproBNP may have therapeutic
consequences for patients with HCY. In patients
with known congestive HF, elevated plasma BNP
concentrations could be reduced by treatment with
ACE inhibitors (21), and angiotensin II receptor
antagonists (22) as well as treatment with diuretics
and vasodilators (23). Cytokines play an important
role in chronic HF. High levels of IL-6 have been
shown in HF by several studies (7, 8). Our results
showing high levels of circulating IL-6 in HCV-
patients are in agreement with other studies present
in literature on HCV-patients, that have demonstrated
high circulating levels in these patients (9, 10).
However, few studies reported no increase of IL-6
levels in HCV (24).
It has been hypothesized that IL-6, as a potent
proinflammatory cytokine, by itself may exacerbate
the damage resulting from minor myocardial
necrosis/injury or may itselfstimulate muscle atrophy
and myocardial failure during the development of
HF. IL-6 and NTproBNP have been shown to be
independent predictors of long-term risk of death for
HF (7). This finding is in agreement with the results
of our study; in fact, no relationship was observed
between IL-6 and NTproBNP.
It has been shown that the combining
measurements of IL-6 and NTproBNP seems to be
a promising tool in the prognostic assessment of HF
patients (8). However, even if we have shown that
NTproBNP and IL-6 are both high in the circulation
of HCV-patients, we cannot exclude that different
pathways may be differently involved in the increase
of each of them.
In conclusion, this is the first study reporting
elevated levels of NTproBNP in HCV-patients
in association with IL-6. This may indicate the
presence of cardiac dysfunction and explain, at least
in part, some of the clinical symptoms of patients
with HCV (1, 2, 4, 25). Further prospective studies
quantifying the symptoms and correlating them with
echocardiographic parameters are needed to confirm
this association.
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